Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?

Vertex Pharmaceuticals Incorporated (VRTX) is scheduled to report second-quarter 2024 results on Aug 1, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $2.65 billion, while the same for earnings is pinned at $4.04 per share. Factors Shaping Upcoming Results In the past 30 days, estimates for Vertex's 2024 earnings per share (EPS) have remained constant at $16.78. During the same time frame, the forecast for the company's 2025 EPS has deteriorated from ...